U.S. Trial of Lilly Antibody Therapy to End; No Safety Issue
5 years ago 1 min read
A paused clinical trial of an Eli Lilly & Co. experimental antibody therapy won’t resume after researchers concluded the drug likely wouldn’t help hospitalized Covid-19 patients with advanced cases.
More Stories
Record Korean Cases; Trader’s Guide to Rollout: Virus Update
California Hits Record; Trader’s Guide to Rollout: Virus Update
AstraZeneca to Buy Alexion for $39 Billion in Rare-Disease Push